Cancer and bone fractures in observational follow-up of the RECORD study

Acta Diabetologica

Volumn 52, Issue 3, 2015, Pages 539-546

  Jones, Nigel P ^a   Curtis, Paula S ^a   Home, Philip D ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Cancer; Fracture; RECORD; Rosiglitazone

Indexed keywords

ANTIDIABETIC AGENT; HEMOGLOBIN A1C; METFORMIN PLUS ROSIGLITAZONE; METFORMIN PLUS SULFONYLUREA; PIOGLITAZONE; ROSIGLITAZONE PLUS SULFONYLUREA; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; METFORMIN; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; BLADDER CANCER; BODY MASS; CANCER REGISTRY; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE DURATION; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; FRACTURE; GALLBLADDER CANCER; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY CANCER; LEUKEMIA; LIVER CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; STOMACH CANCER; UTERUS CANCER; VAGINA CANCER; AGED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; DIABETES MELLITUS, TYPE 2; FRACTURES, BONE; METABOLISM; MIDDLE AGED; NEOPLASMS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; FRACTURES, BONE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; NEOPLASMS; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 84930089577     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-014-0691-y     Document Type: Article

References (18)

1. El-Hage J. http://www.fda.gov/ohrms/dockets/ac/05/slides/2005-4169s2_02_02-fda-elhage.ppt. Accessed Aug 2014
2. Home PD, Kahn SE, Jones NP, Noronha D, Beck-Nielsen H, Viberti G (2010) Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia 53:1838–1845
3. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O’Neill MC, Zinman B, Viberti G, ADOPT Study Group (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427–2443
4. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJV (2009) Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373:2125–2135
5. Dormandy J, Bhattacharya M, de Bruyn ARV, Investigators P (2009) Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes an overview of data from PROactive. Drug Saf 32:187–202
6. Home PD, Pocock SJ, Beck-Nielsen H et al (2005) Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia 48:1726–1735
7. Lefebvre A-M, Chen I, Desreumaux P et al (1998) Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6 J-APCmin/+ mice. Nat Med 4:1053–1057
8. Saez E, Tontonoz P, Nelson MC (1998) Activators of the nuclear receptor PPAR gamma enhance colon polyp formation. Nat Med 4:1058–1061
9. Pino MP, Kelley MF, Jayyosi Z (2004) Promotion of colon tumors in c57bl/6j-apcmin/+ mice by thiazolidinedione PPARγ agonists and a structurally unrelated PPARγ agonist. Toxicol Pathol 32:58–63
10. Dormandy JA, Charbonnel B, Eckland DJ et al (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro-Vascular Events): a randomised controlled trial. Lancet 366:1279–1289
11. Bosetti C, Rosato V, Buniato D, Zambon A, La Vecchia C, Corrao G (2013) Analysis cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis. Oncologist 18:148–156
12. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Yee D et al (2010) Diabetes and cancer: a consensus report. CA Cancer J Clin 60:207–221
13. Hatton JL, Yee LD (2008). Clinical use of PPARγ ligands in cancer. PPAR Res. doi:10.1155/2008/159415
14. He X, Esteva FJ, Ensor J, Hortobagyi GN, Lee M-H, Yeung S-CJ (2012) Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2 + breast cancer. Ann Oncol 23:1771–1780
15. Monami M, Dicembrini I, Mannucci E (2014) Thiazolidinediones and cancer: results of a meta-analysis of randomized clinical trials. Acta Diabetol 51:91–101
16. Lyles BE, Akinyeke TO, Moss PE, Stewart LV (2009) Thiazolidinediones regulate expression of cell cycle proteins in human prostate cancer cells via PPARgamma-dependent and PPARgamma-independent pathways. Cell Cycle 8:268–277
17. Govindarajan R, Ratnasinghe L, Simmons DL, Siegel ER, Midathada MV, Kim L, Kim PJ, Owens RJ, Lang NP (2007) Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol 25:1476–1481
18. Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular disease. N Engl J Med 356:2457–2471